Form 8-K - Current report:
SEC Accession No. 0001558370-18-006443
Filing Date
2018-08-06
Accepted
2018-08-06 16:01:51
Documents
4
Period of Report
2018-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gemp-20180731x8k.htm 8-K 59044
2 EX-4.1 gemp-20180731ex416ef151f.htm EX-4.1 100879
3 EX-10.1 gemp-20180731ex101f436e2.htm EX-10.1 80940
4 EX-99.1 gemp-20180731ex991c2464b.htm EX-99.1 25860
  Complete submission text file 0001558370-18-006443.txt   267960
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 18994711
SIC: 2834 Pharmaceutical Preparations